insights_auto
Why is RGEN down 2.02%?
Dive Deeperchevron_right
RGEN:NASDAQ
Repligen Corp
$163.84
arrow_downward
-2.02%(-3.38) 1D
$163.84
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 8, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RGEN...
Open
$164.00
High
$164.65
Low
$157.44
Mkt. cap
10.40B
Avg. vol.
1.15M
Volume
867.92K
P/E ratio
223.33
52-wk high
$198.86
52-wk low
$100.99
EPS
$0.73
Beta
1.08
Shares outstanding
63.49M
No. of employees
2K
Open
$164.00
High
$164.65
Low
$157.44
Mkt. cap
10.40B
Avg. vol.
1.15M
Volume
867.92K
P/E ratio
223.33
52-wk high
$198.86
52-wk low
$100.99
EPS
$0.73
Beta
1.08
Shares outstanding
63.49M
No. of employees
2K
News stories
From web sources and news partners
TipRanks
·
5 hours ago
Repligen Sinks After BioLife Deal Sparks Investor Jitters
Stock Titan
·
1 day ago
One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake.
Stock Titan
·
1 day ago
Repligen (RGEN) CEO sells shares at $190 and $178.75 under a preset trading plan.
Investing.com
·
2 days ago
Repligen completes acquisition of BioLife Solutions
Profile
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN. Wikipedia
About Repligen Corp
CEOTony J. Hunt
Employees2K
Founded1981
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websiterepligen.com